Literature DB >> 17919427

[Longitudinal study of different metastatic patterns in the progression of cutaneous melanoma].

A Tejera-Vaquerizo1, M V Barrera-Vigo, I Fernández-Canedo, N Blázquez-Sánchez, M Mendiola-Fernández, A Fernández-Orland, R Bosch-García, M de Troya-Martín, E Herrera-Ceballos.   

Abstract

INTRODUCTION: Compared with other tumors, melanoma has displayed one of the largest increases in incidence in recent years, and it is known to have a high metastatic potential. In cases of metastasis, approximately two-thirds of patients have lymph-node metastases and one-third develop systemic metastases. However, few studies have been reported that analyzed different metastatic patterns according to the natural history of melanoma. The main aim of this study was to analyze the different metastatic pathways and patterns and to assess the time course of development of metastases from cutaneous melanoma.
MATERIAL AND METHODS: A retrospective study was performed in 575 patients with onset of primary melanoma between 1990 and 2004. During follow-up, 67 patients developed metastases. Different pathways for metastasis were established and evaluated. We identified 4 metastatic pathways according to the metastatic pattern during progression of the melanoma. The time course of metastases was also evaluated. Finally, we analyzed melanomas with local recurrence in terms of whether or not systemic progression occurred.
RESULTS: Melanoma metastases first occurred in local lymph nodes in 55.2 % of the patients. Initial metastasis was systemic in 14.9 % of the patients. The anatomical location and tumor thickness influenced which metastatic pathway was followed. Distant metastases occurred after a mean of 25 months regardless of the pathway followed
CONCLUSIONS: The development of distant metastases displays a constant time course and the time to onset is independent of the metastatic pathway. This observation may explain why sentinel lymph node biopsy has a limited impact on overall survival of melanoma patients.

Entities:  

Mesh:

Year:  2007        PMID: 17919427

Source DB:  PubMed          Journal:  Actas Dermosifiliogr        ISSN: 0001-7310


  8 in total

1.  Risk Factors for Lymphatic and Hematogenous Dissemination in Patients With Stages I to II Cutaneous Melanoma.

Authors:  Laura Calomarde-Rees; Rosario García-Calatayud; Celia Requena Caballero; Esperanza Manrique-Silva; Víctor Traves; Zaida García-Casado; Virtudes Soriano; Rajiv Kumar; Eduardo Nagore
Journal:  JAMA Dermatol       Date:  2019-06-01       Impact factor: 10.282

2.  Time course and pattern of metastasis of cutaneous melanoma differ between men and women.

Authors:  Liljana Mervic
Journal:  PLoS One       Date:  2012-03-06       Impact factor: 3.240

3.  Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma.

Authors:  Jacqueline Dinnes; Lavinia Ferrante di Ruffano; Yemisi Takwoingi; Seau Tak Cheung; Paul Nathan; Rubeta N Matin; Naomi Chuchu; Sue Ann Chan; Alana Durack; Susan E Bayliss; Abha Gulati; Lopa Patel; Clare Davenport; Kathie Godfrey; Manil Subesinghe; Zoe Traill; Jonathan J Deeks; Hywel C Williams
Journal:  Cochrane Database Syst Rev       Date:  2019-07-01

4.  Tumour mutation status and sites of metastasis in patients with cutaneous melanoma.

Authors:  Nikki R Adler; Rory Wolfe; John W Kelly; Andrew Haydon; Grant A McArthur; Catriona A McLean; Victoria J Mar
Journal:  Br J Cancer       Date:  2017-08-08       Impact factor: 7.640

5.  Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy.

Authors:  April K S Salama; Nicole de Rosa; Randall P Scheri; Scott K Pruitt; James E Herndon; Jennifer Marcello; Douglas S Tyler; Amy P Abernethy
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

6.  Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors.

Authors:  Faruk Tas
Journal:  J Oncol       Date:  2012-06-27       Impact factor: 4.375

7.  Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy.

Authors:  Nikki R Adler; Rory Wolfe; Grant A McArthur; John W Kelly; Andrew Haydon; Catriona A McLean; Victoria J Mar
Journal:  Br J Cancer       Date:  2018-05-14       Impact factor: 7.640

8.  Sentinel Lymph Node Biopsy vs. Observation in Thin Melanoma: A Multicenter Propensity Score Matching Study.

Authors:  Antonio Tejera-Vaquerizo; Aram Boada; Simone Ribero; Susana Puig; Sabela Paradela; David Moreno-Ramírez; Javier Cañueto; Blanca de Unamuno-Bustos; Ana Brinca; Miguel A Descalzo-Gallego; Simona Osella-Abate; Paola Cassoni; Sebastian Podlipnik; Cristina Carrera; Sergi Vidal-Sicart; Ramón Pigem; Agustí Toll; Ramón Rull; Llucìa Alos; Celia Requena; Isidro Bolumar; Víctor Traves; Ángel Pla; Almudena Fernández-Orland; Ane Jaka; María Teresa Fernández-Figueras; Nina Anika Richarz; Ricardo Vieira; Rafael Botella-Estrada; Concepción Román-Curto; Lara Ferrándiz-Pulido; Nicolás Iglesias-Pena; Carlos Ferrándiz; Josep Malvehy; Pietro Quaglino; Eduardo Nagore
Journal:  J Clin Med       Date:  2021-12-15       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.